Mechanism of Action:
Acalabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), which is a key enzyme involved in B-cell receptor signaling.
BTK plays a crucial role in the survival and proliferation of B cells, including cancerous B cells.
Acalabrutinib binds covalently to BTK, irreversibly inhibiting its activity.
By blocking BTK, acalabrutinib disrupts the signaling pathway that regulates the growth and survival of cancerous B cells, leading to cell death and inhibition of tumor growth.
This targeted mechanism of action makes acalabrutinib particularly effective against B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Indications and Uses:
Acalabrutinib is primarily indicated for the treatment of certain types of blood cancers, including:
Mantle Cell Lymphoma (MCL): Acalabrutinib is used as a first-line treatment for patients with MCL, a rare and aggressive form of non-Hodgkin lymphoma.
Chronic Lymphocytic Leukemia (CLL): Acalabrutinib is used in the treatment of CLL, a type of leukemia characterized by the overgrowth of abnormal B cells.
Additionally, acalabrutinib may also be prescribed off-label for other B-cell malignancies or as part of clinical trials investigating its efficacy in different types of cancers.
Acalabrutinib is available in the form of oral tablets.
The recommended dosage and treatment schedule may vary depending on the specific indication and the patient's individual factors, such as age, overall health, and previous treatments.
It is typically taken orally, with or without food, at the prescribed dose and frequency as directed by a healthcare professional.
Common side effects associated with acalabrutinib may include:
Bruising or bleeding
Upper respiratory tract infection
Muscle or joint pain
Other potential side effects that may occur but are less common include atrial fibrillation (an abnormal heart rhythm), hypertension (high blood pressure), and infections.
It is important to report any unusual or severe side effects to a healthcare professional promptly.
Regular blood tests may be conducted to monitor blood cell counts and assess liver function.
Acalabrutinib may also interact with other medications, so it is essential to inform the healthcare provider about all current medications, including over-the-counter drugs and supplements.
Acalabrutinib is a targeted therapy medication that inhibits the activity of Bruton's tyrosine kinase (BTK), a critical enzyme involved in B-cell receptor signaling.
It is primarily used in the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Acalabrutinib is taken orally in tablet form and may cause side effects such as fatigue, diarrhea, and headache.
It is crucial to communicate any concerns or side effects to a healthcare professional for appropriate management and guidance.